BDNF and gastric cancer: Progression-free survival was significantly longer in patients with metastatic GC presenting with an early increase in serum BDNF levels compared with patients showing an early decrease (not reached vs 4.2 months; hazard ratio, 0.15; 95% CI, 0.03-0.84; P = .03) (Figure 4F).